Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$49 Oh so you missed the pick greater than $ARTH...Too bad.
Bono 500,000 share block near the closing. We are getting close to September 26. Thoughts?
I would guess most of you have sold by this time.
Closure Medical was acquired by JNJ in 2005 for $ 370 million.
On a FULLY DILUTED Basis $ARTH is $ 155 million. That is 42% of the $370 million. $ARTH is way beyond Closure.
JNJ and Baxter control 87% of the hemostasis market.
JNJ acquisition of Closure
http://files.shareholder.com/downloads/JNJ/0x0x51855/55e9c27d-61d0-4001-8eab-386a950a16a7/JNJ_News_2005_3_4_Financial_Releases.pdf
“Being a shareholder in this company, is like watching a cartoon character that begins riding on a go cart and after a minute of animated vehicle morphing he is riding in a Silver Shadow Rolls Royce.”
Bono Why is it tough to purchase???? Thanks
Hey Bono What are you hearing? Thanks
Hi Doc
Biochemist. Interesting.
Another MD PHD Dr. KSS
"I am an MD with an additional PhD in biochemistry, and for the past 20 years, in addition to practicing, being a researcher, and conducting clinical trials, I have been investing in biotech companies. I earned my degrees at a top 10 US institution, where I was an NIH scholar and graduated with top honors."
His PHD: Dr. KSS PHD in Molecular Biology of Coagulation Regulation
Regarding AC5: Still possibly one of the best medicine inventions of all time...a noncoagulant hemostatic agent."
He has been covering ARTH since 2014. Have you followed him?
He has his own forum.
Have you read my previous ARTH posts?
Thank you.
Bono what do you think your 2,5 million shares will be worth? Do you know who the new CEO will be?
Hi tfris Closure Medical sold for $ 370 million in 2005. I worry that if sold out too early we will not get full value.... All this stock requires is patience.
When Dr. Norchi sells I will sell. No Rocket Science just plain Horse Sense.
Bono Thanks. Have you ever tried Anatabloc? It is amazing. Hoping they will bring back some way.
Bono are you still buying? Are you more certain on RCPIQ than you other penny stocks you have talked about in past?
Larger position than Bono's 2.5 million? Was it easy to acquire your position?
jmcgorry@biostage.com
Have you talked with Big guys lately?
I assume the trustee is getting shares.
Have not forgotten. There was 170 million shares outstanding at 6/30/16. You own 1.5%. How many do the six investors own? 80%?
If they did a 10 for one reverse split it would be 17 million. What do you think?
Hi Bono What are your thoughts? It will be one year chapter 7 on 9/28.
Anyone touch base with trustee Bono what are your thoughts
Thanks Bono. How many shares are outstanding now? Are you a shareholder?
If we do not have Anatabloc the next best thing is Metformin---need prescription but easy to obtain.
Derived from a compound found in the French Lilac, metformin has a track record of safety and effectiveness at routine doses of up to 2,000 mg daily.4-
The most commonly prescribed antidiabetic drug is metformin. It has been in use in England since 1958 and in the United States since 1995.
http://www.lifeextension.com/Magazine/2017/4/Metformin-Slashes-Cancer-Risks/Page-01
Will Metformin Become the First Anti-Aging Drug?
Anyone recognize this company?
A peptide invented by these two guys via MIT is about to alter forever the practice of medicine and surgery. You mean you're not invested?
https://twitter.com/KSSMDPhD/status/884827722282827776
Biotech Company Review of Total Capital Raised Since Inception to Market Cap
Generally Biotech companies require a lot of cash capital to achieve results. A few require little capital to achieve their desired results.
$ARTH is the best in the biotech universe as far as lowest capital at $24.74 million with a market cap of $ 89.7 million.
For every dollar Arch has raised it has returned $ 3.625561 in market cap. This is extraordinary.
Arch Therapeutics ARTH $ 24.74 M $ 89.70 M 3.625561
When $ARTH is acquired it will be based on the intellectual property that Dr. Norchi has built up.
Show me another biotech where only a small amount of capital $24.7 milliion has been raised to achieve goals life $ARTH. It is tiny .....
Dr. Norchi aced the competition completely. It was briliant !! Stoke of Genius !! You even missed it.
Go read the Company Presentation to see all the areas Arch is involved. 200 AC5 Applications.
Heck it takes 5-6 years for normal biotech to mature. We are only 4.
It has been a nonevent for years and years. Read the recent Form 10-Q where Arch won in the courts. I wrote on this thread about Arch acing the competition with all their patents.
I have no idea why this thread is so backwards. Please do your own due diligence. People here are trying to get you to sell you shares. Ignore them.
Starting to get interesting. Dr. Rice is a genius.
$ARTH Capital required to complete trials–bottom line dilution should be limited
http://ir.archtherapeutics.com/all-sec-filings/content/0001144204-15-070409/v425708_10k.htm
September 30, 2015 Form 10-K Note the $ 3 – 5 million plus $ 7 – $9 million or TOTAL $ 10 to $ 14 million additional capital required to raise
“With respect to our goals relating to AC5, we currently project requiring at least $3,000,000 – $5,000,000 of additional expenditures to complete the clinical and regulatory milestones to obtain necessary regulatory approval in Europe. We further expect that obtaining regulatory approvals in the U.S., including conducting additional required clinical trials, would require at least an additional $7,000,000 – $9,000,000 in capital. In addition, we further expect to require additional funds for corporate and development programs.
These estimated capital requirements potentially could increase significantly if a number of risks relating to conducting these activities were to occur including, without limitation, those set forth under the heading “Risk Factors” in this filing. We anticipate that our operating and other expenses will continue to increase as we continue to implement our business plan and pursue and achieve these goals. After giving effect to the funds received in past equity and debt financings and assuming our use of that funding at the rate we presently anticipate, as of the date of this filing, we believe that we will have sufficient cash to meet our anticipated requirements through May 2016. We could spend our financial resources much faster than we expect, in which case our current funds may not be sufficient to operate our business for the entire duration of that period.”
So at 9/30/15 ESTIMATED $ 10 to $ 14 million for completion of ALL clinical trials
Money Raised since 9/30/15
2016 Raised $2,708,749 exercise of warrants
Stock private placement $ 3,106,593
Total $ 5,815,342
2017
Net Stock sold in private placement and exercise of warrants and payoff of Debt
$ 5,401,263
Grand Total $ 11,216,605 which is more than the $ 10 million above…which means we are not that far off from completion
Total Capital raised by $ARTH since going public in 2013 $ 24,207,274
I am just totally relaxed about timeframes. IMHO Norchi establishes difficult time deadlines to motivate himself. I just ignore it.
Biotechs take 5 to 10 years on average. This one is so unique I am in for the duration. The appreciation over last two years has been good. Find me a better biotech than this one. IMHO risk is low and return potential is high.
One of these will be doing a JV with Arch---hope for large upfront fee.
Top Manufacturers of Hemostasis Products
1) Johnson & Johnson
2) Abbott Laboratories
3) Baxter International Inc.
4) Becton Dickinson
5) CR Bard Inc.
6) CSL Behring LLC
7) Grifols Worldwide
IMHO $ARTH is most unusual from the standpoint of tiny capital to be committed or raised to reach the endzone for completion of human trials and be acquired. Tiny.
Since going public in 2013 $ARTH has raised $ 24,207,274. As you know Curam is assisting in funding in Europe trials.
Show me another biotech that requires so little capital to success?
I estimate that approximately $ 5 to $ 7 million of additional capital will be required for competition of all human trials. I am hoping whoever does the European JV (Johnson & Johnson, Baxter) will put up a large up front fee.
I guess no one is listening or comprehending. Such is life. Best not to read this board as their is little truth here.
Need to get market price over $1 by 5/17/17 so the split will be at least 4 or 5 maybe 6 FOR 1 to put big cushion.
The market cap is soooo low already $ 11.84 million --how low can it go ?? $ 6 million probably.
37 million shares $ 11.84 million market cap st $.32
4 9.25 million shares $ 11.84 million market cap $ 1.28 per share
5 7.4 million $ 11.84 million market cap $ 1.61 per share
6 6.2 million $ 11.84 million market cap $ 1.90 per share
My bet is 6 for 1.
Estimate that everyone's average purchase price will be over $ 2.50 to $ 3.50 per share.
You are the only one that posts proprietary information. I have stopped posting on ARTH because of it. Your information is mostly untrue and old,
LOL Right. Why noone posts about ARTH any longer.
So if they go over 5% they have to file a 13D or 13G. Those three investors have been unwilling to do so.
They normally flip out but they have a ton of shares to unload. Plus the warrants when they are in the money. They participated in the 2015 and 2016 private placements but they doubled down on this one. $ 6 million versus 2015 and 2016 $ 3 million total private placement.
Have to watch and see.
Please READ the ARCH Form 8-K
So Anson, CVI and Intracoastal are part of the original 9 investors that got 3 warrants for 1 share in 2013 that did not work out as they thought. This created the opportunity for all of us to purchase.
These three probably have "Blocker" provisions that prohibit them from going over 5%. Means they sell shares when they exercise Warrants.
So these three normally make a quick $$ and sell.They had to be selling today and I would think tomorrow. Interesting to see.
What is important Arch got the $$$.
http://ir.archtherapeutics.com/all-sec-filings/content/0001144204-17-009992/0001144204-17-009992.pdf
Director James Sulat only took 1.64% of the offering.
–Anson Investments bought 3,333,333 shares.
–CVI Investments bought 3,333,333 shares.
–Intracoastal Capital bought 3,333,333 shares.
–James Sulat’s 3 trusts bought a combined total of only 166,665 shares.
With a FDA like this Anatabloc would still be available
http://www.businessinsider.com/how-fda-drug-approval-works-2017-2
Agree the Float is tiny
https://www.dropbox.com/s/kz81g0kv2b4u9ie/CLRB%20Capital.xlsx?dl=0
What?
What???